- 1D
- 3D
- 1W
- 1M
- 6M
- 1Y
- 3Y
- 5Y
Announcements
- Results from Phase 3 paediatric study
- Interim results
- ACCRUFeR® Approved by Health Canada
- Notice of interim results
- Unaudited Q2 2024 Trading Update
- Directorate Change
- $5.7m Milestone Monetization Agreement with AOP
- Results of 2024 Annual General Meeting
- New Drug Application for Accrufer® in South Korea
- Audited results for the year ended 31 Dec 2023
More ▼
Key statistics
On Friday, Shield Therapeutics PLC (STX:LSE) closed at 4.80, 351.76% above the 52 week low of 1.06 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.85 |
---|---|
High | 4.80 |
Low | 4.74 |
Bid | 4.50 |
Offer | 4.90 |
Previous close | 4.75 |
Average volume | 3.38m |
---|---|
Shares outstanding | 782.06m |
Free float | 294.01m |
P/E (TTM) | -- |
Market cap | 32.89m GBP |
EPS (TTM) | -0.0477 GBP |
Data delayed at least 20 minutes, as of Sep 27 2024 16:01 BST.
More ▼